Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Breast Cancer Research and Treatment

• Publication date

  2013-11-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10549-013-2774-9PMID 24258259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methylation of BRCA1 Promoter Region Is Associated with Unfavorable Prognosis in Women with Early-Stage Breast Cancer

  2013cited by this paper
• Promoter methylation of BRCA1 in triple-negative breast cancer predicts sensitivity to adjuvant chemotherapy.

  2013cited by this paper
• Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma

  2013cited by this paper
• Epigenetic markers of early tumor development.

  2012cited by this paper
• Epigenetic events associated with breast cancer and their prevention by dietary components targeting the epigenome.

  2012cited by this paper
• The Prognostic Role of RASSF1A Promoter Methylation in Breast Cancer: A Meta-Analysis of Published Data

  2012cited by this paper
• BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer

  2012cited by this paper
• Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.

  2012cited by this paper
• Contribution of epigenetic alteration of BRCA1 and BRCA2 genes in breast carcinomas in Tunisian patients.

  2012cited by this paper
• DNA methylation-based biomarkers in serum of patients with breast cancer.

  2012cited by this paper
• Integrating Breast Cancer Genetics into Clinical Practice

  2012cited by this paper
• Minimal residual disease and circulating tumor cells in breast cancer

  2011cited by this paper
• Methylation profiling with a panel of cancer related genes: Association with estrogen receptor, TP53 mutation status and expression subtypes in sporadic breast cancer

  2011cited by this paper
• Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis

  2011cited by this paper
• Determination of the methylation status of MGMT in different regions within glioblastoma multiforme

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Quantitative DNA methylation and recurrence of breast cancer: A study of 30 candidate genes

  2011cited by this paper
• Cell-free DNA in the circulation as a potential cancer biomarker.

  2011cited by this paper
• Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

  2010cited by this paper
• Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.

  2010cited by this paper
• Breast cancer prognostic classification in the molecular era: the role of histological grade

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• BRCA1 promoter methylation is associated with increased mortality among women with breast cancer

  2009cited by this paper
• BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer

  2009cited by this paper
• Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in Tunisian Patients with Invasive Breast Carcinoma

  2009cited by this paper
• Prognostic Relevance of Promoter Hypermethylation of Multiple Genes in Breast Cancer Patients

  2009cited by this paper
• Genetic risk of breast cancer.

  2009cited by this paper
• Multigene Methylation in Serum of Sporadic Chinese Female Breast Cancer Patients as a Prognostic Biomarker

  2008cited by this paper
• More than numbers: the power of graphs in meta-analysis.

  2008cited by this paper
• The epigenomics of cancer.

  2007cited by this paper
• Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases.

  2007cited by this paper
• Practical methods for incorporating summary time-to-event data into meta-analysis

  2007cited by this paper
• Effect of screening and adjuvant therapy on mortality from breast cancer.

  2006cited by this paper
• Effect of screening and adjuvant therapy on mortality from breast cancer

  2005cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Cell-free DNA: measurement in various carcinomas and establishment of normal reference range.

  2002cited by this paper
• BRCA1: mechanisms of inactivation and implications for management of patients.

  2002cited by this paper
• Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis

  2001cited by this paper
• Aberrant methylation of gene promoters in cancer---concepts, misconcepts, and promise.

  2000cited by this paper
• Cancer-epigenetics comes of age

  1999cited by this paper
• Quantitative Synthesis in Systematic Reviews

  1997cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Meta-analysis in the design and monitoring of clinical trials.

  1996cited by this paper
• Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.

  1994cited by this paper
• Linkage of early-onset familial breast cancer to chromosome 17q21.

  1990cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Statistical aspects of the analysis of data from retrospective studies of disease.

  1959cited by this paper

• Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer

  2026cites this paper
• DNA methylation as an oncogenic driver in breast cancer: Therapeutic targeting via epigenetic reprogramming of DNA methyltransferases.

  2025cites this paper
• A review of the use of tumour DNA methylation for breast cancer subtyping and prediction of outcomes

  2025cites this paper
• Molecular targets and therapies associated with poor prognosis of triple-negative breast cancer (Review)

  2025cites this paper
• BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine

  2024cites this paper
• Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA

  2023cites this paper
• Therapeutic effect of iturin A on Candida albicans oral infection and its pathogenic factors

  2023cites this paper
• BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach

  2023cites this paper
• Early diagnosis of ovarian cancer based on methylation profiles in peripheral blood cell-free DNA: a systematic review

  2023cites this paper
• Role of DEK in carcinogenesis, diagnosis, prognosis, and therapeutic outcome of breast cancer: An evidence-based clinical review.

  2022cites this paper
• Correlation analysis between expression levels of BRCA1 and SQLE in cross-subtype diversity of breast cancer and prognosis

  2022cites this paper
• Exceptional behavior of breast cancer-associated type 1 gene in breast invasive carcinoma

  2022cites this paper
• Association of variably methylated tumour DNA regions with overall survival for invasive lobular breast cancer

  2021influential citation
• Identification of epigenetic regulators in the estrogen signaling pathway via siRNA screening.

  2021cites this paper
• Recent advances of dendrimers as multifunctional nano-carriers to combat breast cancer.

  2021cites this paper
• Dietary fat and obesity as modulators of breast cancer risk: Focus on DNA methylation

  2020influential citation
• Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.

  2019cites this paper
• Relationship Between DNA Methylation in Key Region and the Differential Expressions of Genes in Human Breast Tumor Tissue

  2019cites this paper
• Epigenetic Epidemiology for Cancer Risk

  2018cites this paper
• Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.

  2018cites this paper
• TIPE3 hypermethylation correlates with worse prognosis and promotes tumor progression in nasopharyngeal carcinoma

  2018cites this paper
• Epigenetic Signatures in the Diagnosis and Prognosis of Cancer

  2018cites this paper
• Breast Cancer Intra-Tumor Heterogeneity: One Tumor, Different Entities.

  2017cites this paper
• The methylated oligonucleotide-induced methylation of DKK3 promoter promotes the malignant properties of osteosarcoma cells

  2017cites this paper
• Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer

  2017cites this paper
• The role of BRCA status on prognosis in patients with triple-negative breast cancer

  2017influential citation
• Identification of circular RNAs as a promising new class of diagnostic biomarkers for human breast cancer

  2017cites this paper
• Breast Cancer: Exploring the Facts and Holistic Needs during and beyond Treatment

  2017cites this paper
• Aberrant promoter methylation of cancer-related genes in human breast cancer

  2016cites this paper
• Identification and frequency of the rs12516 and rs8176318 BRCA1 gene polymorphisms among different populations.

  2016cites this paper
• Biomarkers in ductal carcinoma in situ

  2016cites this paper
• Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA

  2016cites this paper
• Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis

  2016cites this paper
• Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer

  2015cites this paper
• Promoter methylation of BRCA 1 is associated with estrogen , progesterone and human epidermal growth factor receptor ‐ negative tumors and the prognosis of breast cancer : A meta ‐ analysis

  2015influential citation
• Contributions of DNA methylation aberrancies in shaping the cancer epigenome

  2015cites this paper
• Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.

  2015cites this paper
• Epigenetic changes in BRCA1-mutated familial breast cancer.

  2015cites this paper
• Breast Cancer: Epidemiology and Etiology

  2015cites this paper
• Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies

  2015cites this paper
• Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapy

  2015influential citation
• Epigenetic alterations in cancer and personalized cancer treatment.

  2015cites this paper
• The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment

  2015cites this paper
• Title FOXA 1 repression is associated with loss of BRCA 1 and increased promoter methylation and chromatin silencing in breast cancer

  2014cites this paper
• Methylation profiling of ductal carcinoma in situand its relationship to histopathological features

  2014cites this paper
• FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer

  2014cites this paper
• Epigenetic epidemiology of cancer.

  2014cites this paper